Jeff D. Thostenson

Biostatistician II

UAMS

Last publication 2026 Last refreshed 2026-05-16

faculty

16 h-index 46 pubs 1,764 cited

Research Areas

Links

ORCID Research Group

OverviewAI-generated summary

Jeff D. Thostenson's research, as evidenced by his publications, primarily focuses on bone metabolism and its related disorders, with a particular emphasis on osteocyte function, osteoclast activity, and the effects of aging and genetic factors on bone health. His work investigates the molecular mechanisms underlying bone resorption and formation, including the roles of specific proteins like osteoprotegerin and collagen, and the influence of mitochondrial deacetylation by SIRT3 in osteoclasts. Thostenson has also contributed to studies examining withdrawal paradigms for substance use and the reliability of clinical testing in orthopedic contexts, such as knee arthroplasty. His publications include research on Graves' disease recurrence and the utility of CRISPR interference technology for cell type specificity. He has collaborated with several researchers at the University of Arkansas for Medical Sciences, including Charles A. O’Brien, Joseph J. Goellner, Elena Ambrogini, and Michela Palmieri.

Metrics

h-index: 16
Publications: 46
Citations: 1,764

Selected Publications

Dissecting primary versus secondary effects of osteogenesis imperfecta on abnormal lung development and function (2026)

DOI OpenAlex
Randomized, placebo-controlled trial of gabapentin during outpatient buprenorphine-assisted taper and transition to injectable naltrexone (2025)

1 citation DOI OpenAlex
Discontinuation of levothyroxine therapy in patients with subclinical hypothyroidism: a pilot randomized clinical trial (2025)

4 citations DOI OpenAlex
Elevation of master autophagy regulator Tfeb in osteoblast lineage cells increases bone mass and strength (2025)

6 citations DOI OpenAlex
Exploratory study of heart rate variability among participants with opioid use disorder inducted on gabapentin versus placebo during outpatient buprenorphine-assisted transition to injection naltrexone. (2025)

DOI OpenAlex
Potent suppression of bone remodeling by denosumab does not blunt the anabolic response to romosozumab in mice (2025)

2 citations DOI OpenAlex
Sirtuin-3 promotes osteoclast maturation and bone loss by regulating mitochondrial ROS production during ionizing radiation exposure (2025)

1 citation DOI OpenAlex
A randomized clinical trial of disulfiram at higher doses for the treatment of cocaine use disorder among methadone-stabilized patients (2025)

DOI OpenAlex
Plasma levels of anti phosphocholine IgM antibodies are negatively correlated with bone mineral density in humans (2025)

1 citation DOI OpenAlex
A Predictive Model for Graves’ Disease Recurrence After Antithyroid Drug Therapy: A Retrospective Multicenter Cohort Study (2024)

5 citations DOI OpenAlex
A new <i>Col1a1</i> conditional knock-in mouse model to study osteogenesis imperfecta (2024)

2 citations DOI OpenAlex
CRISPR activation of <i>Tfeb</i> , a master regulator of autophagy and lysosomal biogenesis, in osteoblast lineage cells increases bone mass and strength (2024)

1 citation DOI OpenAlex
Frequency and Determinants of Levothyroxine Therapy Initiation for Veterans with Subclinical Hypothyroidism (2024)

2 citations DOI OpenAlex
THE IMPACT OF FENTANYL ON TREATMENT OUTCOMES DURING AN OUTPATIENT BUPRENORPHINE TAPER WITH ADJUNCT GABAPENTIN (2024)

DOI OpenAlex
CANNABINOID-INVOLVED EXPOSURES, ED VISITS AND HOSPITALIZATIONS BEFORE AND AFTER ARKANSAS MEDICAL MARIJUANA LAW ENACTMENT: INITIAL TRENDS (2024)

DOI OpenAlex